Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）
Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）
Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of
 morbidity, mortality and disability. A large number of studies have confirmed that the
 thrombolytic therapy can effectively open blood vessels and improve the functional prognosis
 of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment
 to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients
 receiving thrombolysis will have good prognosis, while a large number of patients will still
 be disabled and even dead. How to improve the neurofunction prognosis of thrombolytic
 patients has been a hot topic in the world.

 Recent studies have found that the combined application of argatroban and rt-PA in the
 treatment of acute anterior circulation infarction might improve the clinical prognosis and
 not significantly increase bleeding. Some studies have reported that the combined application
 of argatroban and rt-PA could improve the blood vessel opening rate, and prevent re-occlusion
 after opening.

 Based on the discussion, the present study is designed to explore the efficacy and safety of
 argatroban plus rt-PA in the treatment of acute posterior circulation infarction.
Inclusion Criteria:

 1. 18-80 years old;

 2. Diagnosis of posterior circulation ischemic stroke;

 3. Time from onset to treatment ≤6 hours;

 4. NIHSS: 4-25;

 5. Signed informed consent by patient self or legally authorized representatives.

 Exclusion Criteria:

 1. mRS≥2;

 2. History of stroke within 3 months;

 3. History of intracranial hemorrhage;

 4. Suspected subarachnoid hemorrhage;

 5. Intracranial tumour, vascular malformation or arterial aneurysm;

 6. Major surgery within 1 month;

 7. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;

 8. Platelet count < 105/mm3;

 9. Heparin therapy or oral anticoagulation therapy within 48 hours;

 10. Abnormal APTT;

 11. Thrombin or Xa factor inhibitor;

 12. Severe disease with a life expectancy of less than 3 months;

 13. Blood glucose < 50 mg/dL (2.7mmol/L);

 14. Patients who have received any other investigational drug or device within 3 months;

 15. Pregnancy;

 16. Researchers consider patients inappropriate to participate in the registry.